3 results
The purpose of this study is to determine whether, in patients with type II diabetes at high risk for cardiovascular and/or renal events, aliskiren at a target dose of 300 mg o.d. compared to placebo, on top of conventional treatment, reduces…
The primary objective of the study is to evaluate the efficacy of aliskiren, valsartan and a combination of both drugs versus placebo in lowering levels of NT-proBNP in stabilized patients post ACS
To evaluate the effect of cholecalciferol supplection on the systolic blood pressure in hypertensive patients with a 25-hydroxycholecalciferol insufficiency. Secondly, the effects on PRA, aldosteron, 25-hydroxycholecalciferol, alkaline phosphatase,…